Compound 1 with the formula I is an HCV antiviral protide, which is surprisingly soluble in ethanol, thereby facilitating the preparation of pharmaceutical formulations, such as adsorbed mesoporous carriers or SEDDS of Pouton Types III or IV. Compound 1 with the formula I is an HCV antiviral protide, which is surprisingly soluble in ethanol, thereby facilitating the preparation of pharmaceutical formulations, such as adsorbed mesoporous carriers or SEDDS of Pouton Types III or IV. Use of a compound represented by formula (1A), or a pharmaceutically acceptable salt thereof, in the therapy of HCV in a mammal or human, wherein the compound of formula 1A is administered in combination with a further HCV antiviral selected from: a) asunaprevir, daclatasvir and/or beclabuvir； or b) simeprevir and/or JNJ56914845； or c) an HCV protease inhibitor selected from paritaprevir or ABT493, and an NS5A inhibitor selected from ombitasvir or ABT-530； or d) alisporavir； or e) EDP-239； or f) odalasvir and/or sovaprevir； or g) grazoprevir and/or elbasvir.El Compuesto 1 con la fórmula I es un prótido antiviral de VHC, que es sorprendentemente soluble en etanol, por lo tanto, facilitando la preparación de formulaciones farmacéuticas, tales como portadores mesoporosos adsorbidos o SEDDS de Pouton Tipos III o IV.
